STOCK TITAN
  1. Home
  2. Sec-filings
  3. BBIO
  4. [Form 4] BridgeBio Pharma, Inc. Insider Trading Activity

BridgeBio (NASDAQ: BBIO) director receives new RSU and stock option awards

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

BridgeBio Pharma director Andrew Lo reported new equity awards. He received 3,990 restricted stock units of Common Stock and now directly holds 18,079 common shares. Separately, he indirectly holds 50,583 common shares jointly with another holder.

Lo was also granted stock options for 5,277 shares of Common Stock at an exercise price of $68.92 per share, expiring on June 21, 2036. Both the RSUs and the stock options vest in full on June 22, 2027, as long as he continues serving on BridgeBio’s board of directors through that date.

Positive

  • None.

Negative

  • None.
Insider Lo Andrew
Role null
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 5,277 $0.00 --
Grant/Award Common Stock 3,990 $0.00 --
holding Common Stock -- -- --
Holdings After Transaction: Stock Option (Right to Buy) — 5,277 shares (Direct, null); Common Stock — 18,079 shares (Direct, null); Common Stock — 50,583 shares (Indirect, By Andrew W. Lo and Nancy N. Lo JTWROS)
Footnotes (1)
  1. Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The shares underlying the stock option vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.
RSU grant 3,990 units Restricted stock units granted on June 22, 2026
Stock options granted 5,277 options Right to buy Common Stock, granted June 22, 2026
Option exercise price $68.92 per share Conversion or exercise price for 5,277 options
Option expiration June 21, 2036 Expiration date of stock options
Direct common shares after grant 18,079 shares Total direct Common Stock holdings following transactions
Indirect common shares 50,583 shares Indirectly held jointly as JTWROS
RSU vesting date June 22, 2027 Full vesting date for 3,990 RSUs, board service required
restricted stock units ("RSUs") financial
"Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan."
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
Stock Option (Right to Buy) financial
"Stock Option (Right to Buy) with underlying security title Common Stock."
2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan financial
"Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan."
vest in full financial
"The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service."
JTWROS financial
"By Andrew W. Lo and Nancy N. Lo JTWROS"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Lo Andrew
(Last)(First)(Middle)
C/O BRIDGEBIO PHARMA, INC.
3160 PORTER DR., SUITE 250
(Street)
PALO ALTO CALIFORNIA 94304
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
BridgeBio Pharma, Inc. [ BBIO ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/22/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/22/2026A(1)3,990A$0(2)18,079D
Common Stock50,583IBy Andrew W. Lo and Nancy N. Lo JTWROS
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$68.9206/22/2026A5,277 (3)06/21/2036Common Stock5,277$05,277D
Explanation of Responses:
1. Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.
2. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
3. The shares underlying the stock option vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.
Remarks:
/s/ Will Solis, Attorney-in-Fact06/24/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did BridgeBio (BBIO) director Andrew Lo receive in this Form 4 filing?

Andrew Lo received 3,990 restricted stock units and stock options for 5,277 shares of BridgeBio Common Stock. These awards are compensation-related grants rather than open-market purchases or sales of existing shares.

When do Andrew Lo’s new BridgeBio (BBIO) RSUs and options vest?

Both the 3,990 RSUs and the stock options for 5,277 shares vest in full on June 22, 2027, provided Andrew Lo continues serving on BridgeBio’s board of directors through that vesting date.

What is the exercise price and expiration date of Andrew Lo’s BridgeBio stock options?

The newly granted stock options cover 5,277 shares of BridgeBio Common Stock at an exercise price of $68.92 per share. These options expire on June 21, 2036, if not exercised earlier and subject to plan terms.

How many BridgeBio (BBIO) common shares does Andrew Lo hold after these transactions?

After these transactions, Andrew Lo directly holds 18,079 common shares and indirectly holds 50,583 common shares jointly with another person, as reported under joint tenancy with right of survivorship ownership.

Do Andrew Lo’s new BridgeBio RSUs each equal one share of Common Stock?

Yes. Each restricted stock unit represents a contingent right to receive one share of BridgeBio’s Common Stock. The RSUs convert into shares only if the vesting condition through June 22, 2027 is satisfied.

Are Andrew Lo’s BridgeBio equity grants open-market buys or routine awards?

The filing describes the 3,990 RSUs and 5,277 stock options as grants or awards under BridgeBio’s 2021 Amended and Restated Stock Option and Incentive Plan, indicating routine compensation awards rather than open-market buying or selling.